Second Cancer Risk Follows Stem Cell Transplants
Survivors of blood-related cancers who underwent hematopoietic stem cell transplants (HSCT) face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor.
MannKind Corporation Announces Clearance of IND for MKC1106-PP Immunotherapy in Solid Malignancies
The clearance of the IND means that the Company may now proceed with the initiation of its Phase 1 clinical trial – a multicenter, open label, clinical trial of immune response, safety and tolerability of a DNA vector with two synthetic peptides in subjects with solid malignancies, in a plasmid prime-peptide boost treatment.
Colon Cancer Vaccine Shows Promise
British researchers say they’ve developed a vaccine that stimulates the immune system to fight colorectal cancer cells.
Novel Suicide Gene Therapy Used to Treat Malignant Brain Tumors
Physicians and researchers in the Methodist Neurological Institute (NI) are studying the use of a novel combination of radiation and suicide gene therapy to treat typically stubborn malignant brain tumors.
T Cell Therapy Helpful in Metastatic Melanoma
Results of a phase I study indicate that adoptive T-cell therapy using antigen-specific CD8+ T cells prompts immune responses in some patients with metastatic melanoma.
Stem Cell Therapy International Reports the Successful Treatment of a Stroke Patient With Their Proprietary Stem Cell Transplantation Therapy
Stem Cell Therapy International, Inc. announced the successful treatment of a stroke patient from the United States with its stem cell transplantation therapy protocol conducted at one of their affiliate clinics in Kiev, Ukraine.
Study of Gene Transfer for Erectile Dysfunction Shows Promise
The first human study using gene transfer to treat erectile dysfunction (ED) shows promising results and suggests the potential for using the technology to treat overactive bladder, irritable bowel syndrome and asthma.
Northwest Biotherapeutics Receives Institutional Review Board Approval to Accrue Patients in Phase II Brain Cancer Trial
Northwest Biotherapeutics announced that it has received Institutional Review Board (IRB) and contractual approval from the Henry Ford Hospital in Detroit, Michigan to proceed with the Company’s Phase II trial of its personalized therapeutic cancer vaccine, DCVax®-Brain, in patients with newly diagnosed Glioblastoma multiforme (“GBM”).
Face Transplant Woman Can Smile
The recipient of the first partial face transplant has recovered so well she can go out without people noticing her scars, her surgeon has said.
New Rules Proposed to Catch Science Fraud
A panel of scientists and journal editors has advised the high-profile research journal Science to apply tougher standards before publishing certain research.
ABSTRACT, REVIEWS AND SPECIAL REPORTS
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A–specific CTL lines in melanoma patients.